Last reviewed · How we verify
Single ascending doses of MT1013
Single ascending doses of MT1013 is a Small molecule drug developed by Shaanxi Micot Pharmaceutical Technology Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | Single ascending doses of MT1013 |
|---|---|
| Sponsor | Shaanxi Micot Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism (PHASE2)
- MT1013 Clinical TRIAL In Healthy Subject (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single ascending doses of MT1013 CI brief — competitive landscape report
- Single ascending doses of MT1013 updates RSS · CI watch RSS
- Shaanxi Micot Pharmaceutical Technology Co., Ltd. portfolio CI
Frequently asked questions about Single ascending doses of MT1013
What is Single ascending doses of MT1013?
Single ascending doses of MT1013 is a Small molecule drug developed by Shaanxi Micot Pharmaceutical Technology Co., Ltd..
Who makes Single ascending doses of MT1013?
Single ascending doses of MT1013 is developed by Shaanxi Micot Pharmaceutical Technology Co., Ltd. (see full Shaanxi Micot Pharmaceutical Technology Co., Ltd. pipeline at /company/shaanxi-micot-pharmaceutical-technology-co-ltd).
What development phase is Single ascending doses of MT1013 in?
Single ascending doses of MT1013 is in Phase 2.